Brightree to Sell to ResMed for $800 Million

Cooley is advising Brightree on its $800 million sale to ResMed, a tech-driven medical device company and innovator in sleep-disordered breathing and respiratory care. Subject to customary closing conditions, the transaction is anticipated to close by the end of June.

"ResMed Pays $800M for Health Care Software Co. Brightree," Law360

"ResMed Buys Health IT Firm Brightree," The Deal

"Medical-Device Maker ResMed Buys Software Developer Brightree," Mergers & Acquisitions

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.